Abstract | OBJECTIVE: DESIGN: Open labelled clinical study. PATIENTS AND MEASUREMENTS: We prospectively evaluated fasting serum glucose, haemoglobin A(1c) (HbA(1c)), lipid profiles and body weight at baseline and every 3 months after the use of rosiglitazone (4 mg/day) for 18 months in 202 type 2 diabetic patients. RESULTS: TC levels increased maximally at 3 months and decreased thereafter. However, overall, TC levels remained significantly higher at 18 months than those at baseline. LDL-C levels from the 3-month to the 12-month timepoint were significantly higher than those at baseline. However, after 15 months, LDL-C concentrations were not significantly different from basal LDL-C concentrations. HDL-C levels increased after the first 3 months and these levels were maintained. The increment of change in HDL-C was more prominent in patients with low basal HDL-C concentrations than in patients with high basal HDL-C concentrations. Body weight increased after the first 3 months and these levels were maintained. CONCLUSIONS: HDL-C and body weight increased and remained elevated for the duration of the study. There was an initial increase in LDL-C but this attenuated and by the end of the study was not significantly elevated above baseline levels.
|
Authors | Wan Sub Shim, Mi Young Do, Soo Kyung Kim, Hae Jin Kim, Kyu Yeon Hur, Eun Seok Kang, Chul Woo Ahn, Sung Kil Lim, Hyun Chul Lee, Bong Soo Cha |
Journal | Clinical endocrinology
(Clin Endocrinol (Oxf))
Vol. 65
Issue 4
Pg. 453-9
(Oct 2006)
ISSN: 0300-0664 [Print] England |
PMID | 16984237
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Blood Glucose
- Cholesterol, HDL
- Cholesterol, LDL
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin
- Lipids
- Thiazolidinediones
- Triglycerides
- Rosiglitazone
- Cholesterol
|
Topics |
- Adult
- Blood Glucose
(metabolism)
- Body Mass Index
- Body Weight
- Cholesterol
(blood)
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Female
- Glycated Hemoglobin
(analysis)
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Insulin
(blood)
- Lipids
(blood)
- Male
- Middle Aged
- Prospective Studies
- Rosiglitazone
- Thiazolidinediones
(therapeutic use)
- Time
- Triglycerides
(blood)
|